Ifosfamide, carboplatin and etoposide in recurrent malignant glioma

Oncology. 2011;80(5-6):330-2. doi: 10.1159/000330358. Epub 2011 Jul 27.

Abstract

After failure of temozolomide, there is no established standard salvage chemotherapy for patients with recurrent glioblastoma (GBM). Two phase II trials combining ifosfamide, carboplatin and etoposide chemotherapy (ICE) showed favorable results. We therefore applied the ICE protocol to 13 patients (10 GBM, 3 anaplastic astrocytomas). Partial or complete remissions were not observed. None of the 13 patients survived progression-free for 6 months. Our retrospective analysis suggests that the ICE regimen is not effective in patients with recurrent high-grade glioma if applied at second or third relapse.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Astrocytoma / drug therapy*
  • Astrocytoma / secondary
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / pathology
  • Carboplatin / administration & dosage
  • Dacarbazine / analogs & derivatives
  • Dacarbazine / therapeutic use
  • Drug Administration Schedule
  • Etoposide / administration & dosage
  • Female
  • Glioma / drug therapy*
  • Glioma / secondary
  • Humans
  • Ifosfamide / administration & dosage
  • Male
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Temozolomide
  • Treatment Failure

Substances

  • Etoposide
  • Dacarbazine
  • Carboplatin
  • Ifosfamide
  • Temozolomide

Supplementary concepts

  • ICE protocol 3